Breast cancer survival, survival disparities, and guideline-based treatment
- 72 Downloads
The role of appropriate therapy in breast cancer survival and survival disparities by race/ethnicity has not been fully elucidated. We investigated whether lack of guideline-recommended therapy contributed to survival differences overall and among Hispanics relative to non-Hispanic white (NHW) women in a case-cohort study.
The study included a 15% random sample of female invasive breast cancer patients diagnosed from 1997 to 2009 in 6 New Mexico counties and all deaths due to breast cancer-related causes. Information was obtained from comprehensive medical chart reviews. National Comprehensive Cancer Network (NCCN®) guideline-recommended treatment was assessed among white women aged < 70 who were free of contraindications for recommended therapy, had stage I–III tumors, and survived ≥ 12 months. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer death were estimated using Cox proportional hazards models.
Included women represented 4635 patients and 449 breast cancer deaths. Women who did not receive radiotherapy (HR 2.3; 95% CI 1.2–4.4) or endocrine therapy (HR 2.0; 95% CI 1.0–4.0) as recommended by guidelines had an increased risk of breast cancer death, relative to those treated appropriately. Receipt of guideline-recommended therapy did not differ between Hispanic and NHW women for chemotherapy (84.2% vs. 81.3%, respectively), radiotherapy (89.2% vs. 91.1%), or endocrine therapy (89.2% vs. 85.8%), thus did not influence Hispanic survival disparities.
Lack of guideline-recommended radiotherapy or endocrine therapy contributed to survival as strongly as other established prognostic indicators. Hispanic survival disparities in this population do not appear to be attributable to treatment differences.
KeywordsBreast neoplasms Guideline adherence Hispanic americans Healthcare disparities Survival analysis
We would like to thank Ms. Kimberly Cooke, Mr. Nicolas Eldredge, Ms. Rebecca Sando, Ms. Chanel Jim, Mr. Francisco Martinez, Ms. Nancy Brito, and Ms. Georgia Hufnagel for their assistance in conducting this study.
Compliance with ethical standards
Conflict of interest
The authors declare that they do not have any conflict of interest in connection with this manuscript.
- 1.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer. 1997–2009. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology® for Guidelines 1997–2009. ©National Comprehensive Cancer Network, Inc 2010. All rights reserved. To view the most recent and complete version of the guideline. www.nccn.org
- 2.National Cancer Institute (2015) Breast cancer treatment—for health professionals (PDQ®). https://www.cancer.gov/types/breast/hp/breast-treatment-pdq. Accessed 2 Dec 2015
- 3.Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533–1546. https://doi.org/10.1093/annonc/mdv221 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Wockel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L, Group BS (2014) The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol 25(3):628–632. https://doi.org/10.1093/annonc/mdt584 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22(18):3685–3693. https://doi.org/10.1200/JCO.2004.07.018 CrossRefPubMedGoogle Scholar
- 13.Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH (2015) Racial and ethnic differences in breast cancer survival: mediating Effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33(20):2254–2261. https://doi.org/10.1200/JCO.2014.57.1349 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3–IV-18Google Scholar
- 20.Walker GV, Giordano SH, Williams M, Jiang J, Niu J, MacKinnon J, Anderson P, Wohler B, Sinclair AH, Boscoe FP, Schymura MJ, Buchholz TA, Smith BD (2013) Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries. Int J Radiat Oncol Biol Phys 86(4):686–693. https://doi.org/10.1016/j.ijrobp.2013.03.016 CrossRefPubMedGoogle Scholar
- 23.Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588 CrossRefPubMedGoogle Scholar
- 25.Rothman KJ, Greenland S (1998) Measures of effect and measures of association. In: Rothman KJ, Greenland S (eds) Modern epidemiology. Lippincott Williams and Wilkins, Philadelphia, pp 55–56Google Scholar
- 28.Wu X-C, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150CrossRefPubMedGoogle Scholar
- 29.Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278. https://doi.org/10.1200/JCO.2010.31.2835 CrossRefPubMedGoogle Scholar
- 30.Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104(5):406–414CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest oncology studies S8814/S8897. J Clin Oncol 27(13):2157–2162CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Silva A, Rauscher GH, Hoskins K, Rao R, Ferrans CE (2013) Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines. Breast Cancer Res Treat 142(3):667–672. https://doi.org/10.1007/s10549-013-2759-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Centers for Disease Control, National Center for Health Statistics (2008) National Health Statistics Reports. State, Regional and National Estimates of Health Insurance coverage for people under 65 years of age. National Health Interview Survey. https://www.cdc.gov/nchs/data/nhsr/nhsr001.pdf